Key terms

About KPTI

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest KPTI news

Mar 05 3:20am ET Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF) Mar 01 7:28am ET RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI) Mar 01 6:09am ET Karyopharm price target lowered to $8 from $10 at H.C. Wainwright Mar 01 1:02am ET Bad News for Karyopharm Therapeutics INC Stock: This New Risk Has Been Added Feb 29 7:36am ET Karyopharm sees 2024 revenue $140M-$160M, consensus $152.02M Feb 29 7:35am ET Karyopharm reports Q4 EPS (36c), consensus (31c) Feb 26 10:30pm ET Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN) Feb 20 8:14am ET Karyopharm Regains Compliance, Secures Nasdaq Listing Feb 09 9:14am ET Karyopharm CFO Michael Mason sell 4,205 shares Feb 08 11:40am ET Biotech Alert: Searches spiking for these stocks today Feb 07 11:01am ET Biotech Alert: Searches spiking for these stocks today Feb 05 12:27pm ET Morphosys interest highlights Karyopharm’s opportunity in MF, say RBC Capital Jan 22 2:24pm ET Piper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI) Jan 09 7:38am ET Piper Sandler Reaffirms Their Buy Rating on Karyopharm Therapeutics (KPTI) Jan 09 6:30am ET Analysts’ Top Healthcare Picks: Biora Therapeutics (BIOR), Irhythm Technologies (IRTC) Jan 08 8:32am ET Karyopharm sees FY23 revenue $145.9M, consensus $150.03M Jan 08 8:32am ET Karyopharm sees Q4 revenue $33.6M, consensus $37.64M Jan 05 8:47pm ET RBC Capital Keeps Their Buy Rating on Karyopharm Therapeutics (KPTI) Dec 13 1:22am ET Leerink Partners Sticks to Their Hold Rating for Karyopharm Therapeutics (KPTI)

No recent news articles are available for KPTI

No recent press releases are available for KPTI

KPTI Financials

1-year income & revenue

Key terms

KPTI Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

KPTI Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms